Small molecules once dominated drug development, and preclinical testing was built around them. Today's pipeline is different: biologics, cell and gene therapies, mRNA, and antibody-drug conjugates each present distinct testing challenges. The rise of these novel modalities is transforming preclinical CRO services, driving investment in new capabilities and reshaping competitive dynamics in the Preclinical CRO Services Market.

New Testing Paradigms

The primary transformation is methodological. Cell and gene therapies, for example, require specialized assays to assess biodistribution, persistence, and immunogenicity that differ fundamentally from small-molecule toxicology. Biologics demand species-specific testing and immunogenicity assessment. CROs are investing in specialized platforms, animal models, and expertise to serve these modalities, and those that build capabilities early capture disproportionate share.

Demand for Translational Expertise

A second transformation is the demand for translational insight. Novel modalities often lack established biomarkers and reference data, and sponsors increasingly rely on CROs for scientific guidance, not just execution. CROs that can advise on study design, model selection, and regulatory strategy are becoming development partners rather than service vendors, which supports higher-value engagements.

People Also Ask

How are novel modalities changing preclinical testing?
Cell and gene therapies, biologics, and mRNA require specialized assays for biodistribution, persistence, and immunogenicity that differ from traditional small-molecule testing.

Why is translational expertise important in preclinical CROs?
Novel modalities often lack established biomarkers, so sponsors rely on CRO scientific guidance for study design and regulatory strategy.

As novel modalities continue to expand, preclinical CROs with specialized capabilities will be well-positioned to capture growth.

Tags: #PreclinicalCRO #NovelModalities #CellAndGeneTherapy #Biologics #DrugDevelopment